Wright State University

CORE Scholar
Browse all Theses and Dissertations

Theses and Dissertations

2012

Q-ve-oph, A Control Caspase Inhibitor for Analyzing Neuronal
Death
Rebecca L. Bricker
Wright State University

Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all
Part of the Immunology and Infectious Disease Commons, and the Microbiology Commons

Repository Citation
Bricker, Rebecca L., "Q-ve-oph, A Control Caspase Inhibitor for Analyzing Neuronal Death" (2012). Browse
all Theses and Dissertations. 570.
https://corescholar.libraries.wright.edu/etd_all/570

This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE
Scholar. For more information, please contact library-corescholar@wright.edu.

Q-VE-OPh, a control caspase inhibitor for analyzing neuronal death

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

By

REBECCA LYNN BRICKER
B.S., Wright State University, 2010

2012
Wright State University

WRIGHT STATE UNIVERSITY
GRADUATE SCHOOL

June 4, 2012

I HEREBY RECOMMEND THAT THE THESIS PREPARED
UNDER MY SUPERVISION BY Rebecca Lynn Bricker ENTITLED
Q-VE-OPH, A CONTROL CASPASE INHIBITOR FOR
ANALYZING NEURONAL DEATH BE ACCEPTED IN PARTIAL
FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE
OF Master of Science

Thomas L. Brown, Ph.D.
Thesis Director

Barbara Hull, Ph.D.
Program Director
Committee on
Final Examination

Thomas L. Brown, Ph.D.

David Cool, Ph.D.

Courtney Sulentic, Ph.D.

Andrew Hsu, Ph.D.
Dean, Graduate School

ABSTRACT

Bricker, Rebecca Lynn. M.S., Microbiology and Immunology Program, Wright State
University, 2012. Q-VE-OPh, a control caspase inhibitor for analyzing neuronal death.

Sarin is a neurotoxin that has been used in terrorist attacks in Japan and is a
potential bioterrorist weapon. It induces seizures by affecting the regulation of
neurotransmitters in the brain. Seizures are directly correlated to neuronal damage. Two
types of neuronal damage that can occur are apoptosis and necrosis. One of the main
regions of the brain where neuronal death occurs is the hippocampus, which is involved
in memory. Victims showed chronic decline of memory loss 3 and 7 years after the
Tokyo’s terrorist attack incident. There are treatments available that can break down
sarin or can block the continuous activation of acetylcholine by acting as a competitive
antagonist at the acetylcholine receptor, but there are no current treatments that prevent
neuronal death in the brain after sarin exposure. Our overall hypothesis is that the broad
spectrum caspase inhibitor, Quinoline-Val-Asp-Difluorophenoxymethyl ketone (Q-VDOPh), can reduce or prevent caspase-activated neuronal death in the brain thereby,
preventing memory loss. Q-VD-OPh has been shown to prevent all apoptotic pathways
and is not toxic to cells. It is the most effective known caspase inhibitor and has the
ability to cross the blood brain barrier. In order to validate its effectiveness in preventing
neuronal death in sarin-exposed mice, we designed and synthesized the appropriate
iii

negative control by replacing aspartic acid in Q-VD-OPh with glutamic acid, making QVE-OPh. Q-VE-OPh did not prevent DNA laddering or the activation of cleaved caspase
8 or 9. In addition, we found Q-VE-OPh is not toxic in vitro. Q-VE-OPh closely
resembles Q-VD-OPh which provides it as an optimal negative control. Sarin-exposed
mice brains treated with Q-VD-OPh or Q-VE-OPh will be analyzed by
immunohistochemistry.
Due to the use of sarin being restricted to two locations in the United States by the
US Department of Defense, all of our experiments must be done at one time and at the
same facility. Therefore, it was necessary to optimize brain tissue processing techniques,
storage conditions, and the immunohistochemistry assays in mice not exposed to sarin.
The goal of the current work will focus on eliminating background in
immunohistochemistry assays in order to prevent false labeling. The optimizations of
these labeling procedures will be used to determine if neuronal death in the hippocampus
is decreased in sarin-exposed mice treated with Q-VD-OPh compared to sarin-exposed
mice treated with Q-VE-OPh.
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I. INTRODUCTION

What is Sarin?
Sarin, also known as GB, is an organophosphorous cholinesterase inhibitor that is
used as a human-made chemical warfare nerve agent (Figure 1). It is part of the G-series
compounds named after German scientists. It is an odorless and colorless gas that people
can be exposed to through inhalation of vapors or contact with the liquid form. Due to
being the most volatile of the nerve agents, sarin is the preferred chemical warfare agent.
It has a vapor pressure of 2.1 mm Hg which is 16 times higher than other nerve agents
and can remain active in the environment for 2 to 24 hours. Sarin can also produce a
rapid response, with symptoms occurring from seconds to minutes after exposure
(Wiener and Hoffman, 2004).

History
The first organophosphate compounds were synthesized in 1854 and the first
nerve agents were developed in 1936. Nerve agents were originally developed as
pesticides. By the end of World War II, German scientists had developed more types of
nerve agents and produced large quantities that could be deployed as weapons. The
United States and Soviet Union developed their own stockpiles of nerve agents in the
1950’s. In 1984, Iraq had used nerve agents in their war against Iran (Wiener and
Hoffman, 2004). The biggest incidents in which nerve agents were used were in two
1

Figure 1: Chemical structure of sarin
Sarin is an organophosphate cholinesterase inhibitor.

2

Figure 1
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terrorist attacks in Japan (Wiener and Hoffman, 2004). In 1994, the religious cult Aum
Shinrikyo released twelve liters of 70% sarin in a residential area in the city of
Matsumoto, Japan (Nakajima et al., 1998). More than 250 people were exposed of which
56 were admitted to hospitals and 7 people died (Suzuki et al., 1997). A second, much
larger attack occurred in 1995 when the same religious cult released 30% sarin in five
subway cars on three separate subway lines during the Monday morning rush hour
underneath the Japanese National Government’s ministry offices in Tokyo, Japan. In this
attack, 5,500 people needed medical care and 12 died (Yanagisawa et al., 2006). (Table
1)

Effects of Sarin on People
The people exposed to sarin in the terrorist attacks died due to respiratory failure
and severe anoxic brain damage (Yanagisawa et al., 2006). Mild symptoms included
nausea, vomiting, headache, sore throat, constricted pupils, ocular pain, numbness in the
extremities, and respiratory difficulty. The more severely exposed patients experienced
the mild symptoms as well as scattered fasciculation, hallucination, generalized
convulsions, transient cardiac arrhythmias, and a decreased level of consciousness
(Figure 2). The major laboratory finding was a decrease in plasma cholinesterase
activity. Recovery of plasma cholinesterase to normal levels took between 2-3 months
(Okumura et al., 1996; Murata et al., 1997; Suzuki et al., 1997; Nakajima et al., 1998;
Morita et al., 2005; Yanagisawa et al., 2006). Victims from Matsumoto were relieved of
major symptoms and released from the hospital after a month. Mild symptoms still
occurred up to 6 months to a year in a few sarin-exposed people in
4

Table 1: History of sarin
Date
1854
1936
1945
1950
1984
1991
1994
1995

Event
Originally developed in Germany as a pesticide.
First nerve agents were developed.
Germany produced large quantities that could be deployed as weapons.
US and Soviet Union obtained their own stockpiles of nerve agents.
Iraq used nerve agents in their war against Iran.
Labeled as a “Weapon of Mass Destruction” by the United Nations.
The religious cult Aum Shinrikyo released twelve liters of 70% sarin in a
residential area in the city of Matsumoto, Japan.
The religious cult Aum Shinrikyo released 30% sarin in subway cars
underneath the Japanese National Government’s ministry offices in Tokyo,
Japan.

5

Figure 2: Summary of symptoms from sarin exposure
Sarin affects the central and peripheral nervous system. Mild symptoms included
nausea, headache, sore throat, constricted pupils, ocular pain, numbness in the
extremities, and respiratory difficulty. The more severely exposed patients experienced
the mild symptoms plus scattered fasciculation, hallucination, generalized convulsions,
transient cardiac arrhythmias, and a decreased level of consciousness.

6

Figure 2
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Matsumoto (Nakajima et al., 1998; Morita et al., 2005). People who had a pupil diameter
of less than 2mm and a serum cholinesterase level less than 100% were evaluated a year
later. Most had normal results but the more severe patients had electroencephalogram
(EEG) abnormalities that took up to 5 years to return to normal (Yanagisawa et al., 2006).
In the Tokyo attack, 95% of people admitted were released from the hospital within 2 -4
days (Okumura et al., 1996). Five years after sarin poisoning, many still had common
symptoms such as blurred vision, easy fatigability, difficulty in concentration, difficulty
in near vision, and headaches (Murata et al., 1997; Yanagisawa et al., 2006).
Importantly, people exposed to sarin that were evaluated 3 and 7 years afterwards,
showed chronic decline of memory function compared to people who were not exposed
to sarin. (Nishiwaki et al., 2001; Miyaki et al., 2005).

Mechanism
A single nerve impulse in the terminal motor-axon releases acetylcholine which
binds to its receptors and produces a localized depolarization that stimulates a muscle
response. This response is terminated when acetylcholinesterase degrades acetylcholine,
releasing acetylcholine from its receptor (Figure 3a). Sarin binds to and inhibits the
enzyme acetylcholinesterase, preventing acetylcholine from being degraded (Figure 3b).
As a result, acetylcholine builds up and constantly activates its receptor. This causes
continuous transmission of nerve impulses that prevent the muscle or organ from
relaxation, which contributes to seizures (Taylor 1985; Khan 2000; O’Donnell et al.,
2010). Ten hours after sarin exposure, sarin can release a functional group making the
bond between sarin and acetylcholinesterase permanent. The enzyme,
8

Figure 3: Acetylcholine mechanism to trigger nerve impulses
A single nerve impulse in the terminal motor-axon releases acetylcholine which
binds to its receptors and produces a localized depolarization that stimulates a muscle
response. This response is terminated when acetylcholinesterase degrades acetylcholine
releasing it from its receptor (A). Sarin binds to and inhibits the enzyme
acetylcholinesterase which prevents acetylcholine from being degraded (B).
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Figure 3
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acetylcholinesterase, is said to be ‘aged’ and cannot be reactivated. The function of the
enzyme returns once new, unbound acetylcholinesterase has been produced (Wiener and
Hoffman, 2004).

Treatment
There are a few drugs that are used for treatment of sarin nerve poisoning.
Atropine blocks further acetylcholine activation through competitive antagonism with
acetylcholine at its receptor (Figure 4a). Pralidoxime restores acetylcholinesterase by
breaking down the nerve agent bound to it (Figure 4b). The use of pralidoxime is only
effective before the enzyme has aged. Diazepam (Valium) is an anticonvulsant drug that
reduces convulsions and seizures. People who are at a potential risk for chemical
exposure, such as the military, are provided with a Mark I nerve agent antidote kit
(NAAK) (Figure 5a). This consists of 2 auto-injectors that contain atropine and
pralidoxime. There is also an additional auto-injector called convulsion antidote, nerve
agent (CANA) that contains diazepam (Figure5b). These auto-injectors are injected into
the muscle of the thigh or buttock by the individual after exposure (Wiener and Hoffman,
2004).

Seizures cause brain damage
In rats exposed to sarin, 70% that had prolonged convulsions lasting longer than 2
hours also developed brain lesions or neuronal death. Brains lesions were less severe in
rats that only had partial seizures. Lesions were found mainly in CA1 and CA3 regions
of the hippocampus 4 hours post exposure and subsequently in the thalamus and piriform
11

Figure 4: Treatment for sarin poisoning.
Atropine blocks further acetylcholine activation through competitive antagonism
with acetylcholine at its receptor (A). Pralidoxime restores acetylcholinesterase by
breaking down the nerve agent bound to it (B).

Atropine = A
Pralidoxime = P

12

Figure 4
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Figure 5: Mark I nerve agent antidote kit (NAAK) and convulsion antidote, nerve
agent (CANA)
People who are at a potential risk for chemical exposure, such as the military, are
provided with a Mark I nerve agent antidote kit (NAAK) (A). This consists of 2 autoinjectors that contain atropine and pralidoxime. There is also an additional auto-injector
called convulsion antidote, nerve agent (CANA) that contains diazepam (B).

14

Figure 5

http://chemm.nlm.nih.gov/antidote_nerveagents.htm
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cortex 24 hours post exposure. The hippocampus is involved in spatial learning and
memory (Kadar et al., 1995). Sarin-exposed rats had impaired working and reference
memory 1 month post exposure and no recovery of function was detected 6 months post
exposure in water maze memory task (Grauer et al., 2008). Seizures are due to an
increase in excitatory activity which can cause brain damage (Lallement et al., 1992;
Allon et al., 2011). Although atropine and pralidoxime prevent further acetylcholine
activation and diazepam enhances inhibitory activity to suppress seizures, there are no
current drugs that inhibit neuronal death in the brain after sarin exposure.

Neuronal Death
There are different types of neuronal death found in brain lesions after sarin
exposure that could occur: apoptosis and necrosis (Bonfoco et al, 1995; CharriautMarlangue et al., 1996; Leist et al, 1997; Chen et al., 1998; Fujikawa et al.,1999;
Colbourne et al., 2000; Fujikawa et al., 2000; Henshall et al., 2000; Kondratyev et al.,
2000; Benchoua et al, 2001; Niquet et al., 2007; Fujikawa et al., 2010; Lopez-Meraz et
al., 2010a; Lopez-Meraz et al., 2010b). These types of cell death are a form of
programmed cell death that is essential for development, morphogenesis, tissue
remodeling, immune regulation, and occurs in many types of pathologies (Fiers et al.,
1999). Excessive death can contribute to injury which is found to occur in several
diseases such as sepsis, stroke, ischemia, neurodegenerative diseases, diabetes, and
myocardial infarction (Mattson 2000; Duprez et al., 2009).
Apoptosis is the controlled breakdown of the cell into apoptotic cell bodies which
are then rapidly recognized and engulfed by surrounding cells and phagocytes. This
16

process is characterized by cell shrinkage, membrane blebbing, nuclear and cytosolic
condensation, the breakdown of nuclear DNA, and the lack of an inflammatory response
(Fiers et al., 1999; Duprez et al., 2009). There are two apoptotic pathways: intrinsic and
extrinsic. The intrinsic (mitochondrial) pathway is activated by DNA damage and
cytotoxic insult that act through the mitochondria. When there is cellular stress,
cytochrome c is released from the mitochondria and associates with apoptotic protease
activating factor - 1 (Apaf-1), adenosine triphosphate (ATP), and initiator procaspase 9 to
form the apoptosome. The apoptosome activates caspase 9 which leads to the cleavage
and activation of executioner caspases 3, 6, and 7. The extrinsic (death receptor)
pathway is activated by the stimulation of death receptors which activate the deathinducing signaling complex (DISC). DISC has a Fas-associated death domain (FADD)
that recruits and activates initiator caspases 8 and/or 10 which then activate the
executioner caspases 3, 6, and 7. Cysteine-aspartic proteases or caspases mediate
apoptosis (Figure 6) (Kajta 2004; Ribe et al, 2008; Duprez et al., 2009).
Necrosis is caspase independent and is characterized by cytoplasmic and
organelle swelling, loss of cell membrane integrity, nuclear pyknosis, small dispersed
clumps, and the release of cellular contents into extracellular space (Fiers et al., 1999;
Henshall et al., 2000; Duprez et al., 2009). It occurs when cells are exposed to extreme
stress or in neurodegenerative disorders (Syntichaki et al, 2003). Necrotic cell death can
be activated if caspase activation during apoptosis is hampered and can then serve as a
backup pathway via the death receptors (Duprez et al., 2009).
There is controversy over which type of cell death occurs after seizure (Henshall
2007; Wyllie and Golstein 2001; Sperandio et al., 2000; Martin et al., 1998; Leist and
17

Figure 6: Apoptotic Pathway
There are two apoptotic pathways: intrinsic and extrinsic. The intrinsic
(mitochondrial) pathway is activated by DNA damage and cytotoxic insult that act
through the mitochondria. When there is cellular stress, cytochrome c is released from
the mitochondria and associates with apoptotic protease activating factor - 1 (Apaf-1),
adenosine triphosphate (ATP), and initiator procaspase 9 to form the apoptosome. The
apoptosome activates caspase 9 which leads to the cleavage and activation of executioner
caspases 3, 6, and 7.
The extrinsic pathway (B) is activated by the stimulation of death receptors which
activate the DISC. DISC recruits and activates initiator caspases 8 and/or 10 which then
activate the executioner caspases 3, 6, and 7. Caspases 3, 6, and 7 execute the last phase
of apoptosis.

18

Figure 6
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Jäättelä 2001; Nicotera et al., 1999; Fujikawa 2000a; Lee et al., 2000; Choi 1996; Choi
1995; Seo et al., 2009). There are several factors that influence the type of cell death that
occurs: maturity, intensity, and energy levels. The CA1 region matures, physiologically
and anatomically, quicker than the dentate gyrus. In postnatal hippocampal neurons in
rats that were induced to have seizures, the CA1 region died necrotically whereas the
dentate gyrus died apoptotically (Lopez-Meraz et al., 2010b). Low levels of excitotoxic
exposure can induce neurons to undergo apoptosis whereas more intense excitotoxic
exposures deplete the energy supply and induced necrosis (Bonfoco et al, 1995). This is
because ATP acts as a switch between apoptosis and necrosis. In cell culture when there
was plenty of energy, apoptosis occurred and when the energy store was depleted,
necrosis resulted (Leist et al, 1997). Interestingly, apoptosis is found to initially occur in
the core lesion in a model of cerebral infarction. Necrosis dominates in the core or the
initial lesion and apoptosis occurs in the penumbra or the expansion of the core where
there are sufficient energy levels (Charriaut-Marlangue et al., 1996; Benchoua et al.,
2001).
Additionally, there is evidence for a pattern of combined necrotic and apoptotic
cell death (Wyllie and Golstein 2001; Sperandio et al., 2000; Martin et al., 1998; Leist
and Jäättelä 2001; Nicotera et al., 1999; Fujikawa 2000a; Lee et al., 2000; Choi 1996;
Choi 1995; Seo et al., 2009). Ultrastructural studies showed hippocampal neurons died
by necrosis 72 hours after induced-status epilepticus and global ischemia (Fujikawa et
al.,1999; Colbourne et al., 2000; Fujikawa et al., 2000). However, enzymatic studies
showed that Tunel positive cells and caspase 3 activity colocalized together in
hippocampal neurons 24 and 72 hours after induced-status epilepticus and ischemia
20

(Chen et al., 1998; Henshall et al., 2000; Kondratyev et al., 2000). Finally there were
studies that showed hippocampal injured neurons died by a caspase-dependent active
form of necrosis after induced-status epilepticus. The dying cells were morphologically
necrotic but also had active caspase 3 located in the neurons (Niquet et al., 2007; LopezMeraz et al., 2010b). Sarin-induced seizures may initially cause apoptotic cell death but
necrosis may take over if damage is too intense. Since there is caspase activation in both
apoptotic and necrotic death after status epilepticus induced seizures, a caspase inhibitor
may prevent neuronal death in the hippocampus caused by sarin exposure.

Broad Spectrum Caspase Inhibitor
Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxyl]-methyl
ketone) is a non-toxic, broad spectrum caspase inhibitor (Figure 7) that can prevent
apoptosis by inhibiting the activation of all caspase pathways (Caserta et al, 2003)
(Figure 8). Q-VD-OPh specifically inhibits caspases. It contains a quinoline group that
protects the two amino acids, valine and aspartic acid, from degradation. The OPh group
eliminates in vivo toxicity and increases cell membrane permeability. It is the most
effective known caspase inhibitor that can cross the blood brain barrier and has been
shown to be effective in numerous in vivo studies. It reduced neuronal death and
eliminated activated caspase 3 in the hippocampal neurons of rats with induced-status
epilepticus (Lopez-Meraz et al., 2010a). Q-VD-OPh has also been shown to decrease
neuronal death in rats after neonatal stroke (Braun et al., 2007; Renolleau et al., 2007). A
caspase 3 inhibitor, z-DEVD-fmk, reduced neuronal death in the hippocampus of rats
after induced-status epilepticus and ischemia (Chen et
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Figure 7: Structure of Q-VD-OPh.
The quinoline group is the protection group (A). It contains two amino acids:
valine (B) and aspartic acid (C). The OPh group eliminates in vivo toxicity (D). Q-VDOPh is specific for interacting with the pocket of caspases.
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Figure 7
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Figure 8: Q-VD-OPh inhibits caspases in the apoptotic pathway.
Q-VD-OPh prevents the caspases 8/10, 9, and 3 from being activated.
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Figure 8
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al., 1998; Henshall et al., 2000; Kondratyev and Gale, 2000). However, caspase
inhibitors with a ‘fluoromethylketone (fmk)’ containing group have shown to be toxic in
vivo due to the accumulation of fluoroacetate (Schotte et al., 1999; Van Noorden et al.,
2001; Caserta et al., 2003). Since Q-VD-OPh has been shown effective at low
concentrations, non-toxic to cells, and can cross the blood brain barrier (Caserta et al.,
2003), it is the preferred caspase inhibitor to use to prevent neuronal death in the brains
of sarin-exposed mice.

Hypothesis and Aims
Our overall hypothesis is that Q-VD-OPh will reduce or prevent caspase activated
neuronal death in neurons of the hippocampus in sarin-exposed mice. Reducing neuronal
degeneration may help in preventing memory loss for those who are at a high risk of
exposure to nerve agents. The goal of the current work is to provide a negative control
and to optimize protocols to analyze neuronal death in sarin-exposed mice treated with
Q-VD-OPh.
Before Q-VD-OPh effectiveness in preventing neuronal death in sarin-exposed
mice can be evaluated, we needed to design a negative control. The caspase inhibitor, QVE-OPh, was synthesized as an equivalent dipeptide amino acid analog similar to the
broad-spectrum caspase inhibitor, Q-VD-OPh (Southerland et al., 2010). It includes the
addition of a single carbon element to the aspartic acid (D) residue changing it to
glutamic acid (E).
The current negative control for caspase inhibitors is Z-FA-fmk (ZPhenylalanine-Alanine-fluoromethylketone). This does not represent a true negative
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control for caspase inhibitors because it inhibits effector caspases and cathepsin B
(Lopez-Hernandez et al., 2003; Lawerence et al., 2006; Gezginci-Oktayoglu et al., 2008).
Q-VE-OPh would be a better negative control than Z-FA-fmk, because it has similar
features to Q-VD-OPh.
Sarin-exposed mouse brains treated with Q-VD-OPh or Q-VE-OPh will be
analyzed by immunohistochemistry. Tunel assay will detect cell death after sarin
exposure. Neuronal neuron (NeuN) will detect neurons in the brain to show where cell
death occurs in the brain after sarin exposure. Because sarin is restricted by the US
Department of Defense to being used in two places in the United States, all of our
experiments must be done at one time and at the same facility.
Therefore, before we proceed in analyzing sarin-exposed brain sections, it is
critical to optimize brain tissue processing techniques, storage conditions, and the
immunohistochemistry assays in untreated mice as indicated below.

Aim 1
To determine if the caspase inhibitor, Q-VE-OPh, can be used as a negative control for
O-phenoxy-conjugated caspase inhibitors.
Aim 2
To optimize brain processing techniques and storage conditions in mice not exposed to
sarin.
Aim 3
To optimize Tunel assay and NeuN staining by eliminating background and obtaining
optimal contrast between stain and background.
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II. MATERIALS AND METHODS

Materials
Jurkat T cells (clone E6-1) were obtained from ATCC. Caspase 8 antibody was
purchased from Cell Signaling, Inc and caspase 9 antibody was purchased from Santa
Cruz Biotechnology. Actinomycin D was obtained from Calbiochem, Inc. Immobilon P
was purchased from Millipore. Supersignal chemiluminescence reagent was purchased
from Pierce, Inc. Tunel assay was completed by using the NeuroTACS II In Situ
Apoptosis Detection Kit (Trevigen). Avidin-Biotin Conjugate (ABC) was received from
Vector Laboratories. Anti-NeuN was acquired from Millipore Cat #: MAB377. Antimouse biotinylated antibody was bought from Vector Labortories, Cat #: BA-9200.

Production of Q-VD-OPh and Q-VE-OPh
The caspase inhibitor Q-VD-OPh and corresponding negative control Q-VE-OPh
were produced by Apoptrol, LLC (Caserta et al., 2003; Southerland et al., 2010). Briefly,
amino terminally- protected aspartyl or glutamyl groups were converted to—OPh
conjugates and then reacted to elicit the methylated forms of Q-VD (OMe)-OPh and QVE(OMe)-OPh (Caserta et al., 2003; Southerland et al., 2010). This was followed by
HPLC purification. Production of the non-methylated compounds was achieved by
saponification. Q-VD-OPh and Q-VE-OPh were solubilized in DMSO prior to use.
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Cell Culture
Jurkat human T cells were cultured at 1 × 10 6 cells/ml, unless otherwise indicated, in
RPMI 1640 containing 10% FBS and antibiotic/antimycotic. All cells were cultured at
37°C and 95% O2 / 5% CO2 .

Apoptotic DNA Ladder Assays
Jurkat cells (1 × 106 cells/ml) in 10 mls were preincubated 30 minutes with
vehicle, drug alone, or various concentrations of Q-VE-OPh or Q-VD-OPh, prior to
treatment with actinomycin D for 4 hrs. Cytoplasmic DNA was isolated and analyzed for
DNA laddering. Briefly, apoptosis was measured by analysis of an oligonucleosomal
DNA ladder in agarose gels as previously reported (Brown et al., 1998; Brown et al.,
1999; Brown et al., 2000; Caserta et al., 2003). Cells (1 × 107) were centrifuged at 1,000
rpm for 5 min and lysed in HL buffer for 15 min. The lysate was extracted with an equal
volume of phenol, and then phenol:chloroform:isoamyl alcohol (25:24:1), and
precipitated 18 h at −20°C with an equal volume of isopropanol and 0.1 volume of 5 M
NaCl. The precipitated DNA was resuspended in Tris/EDTA, pH 8.0, containing DNasefree RNase A and incubated at 37°C for 30 min. The DNA was analyzed on a 1.2%
agarose gel containing ethidium bromide.

Western Blot
Protein concentrations and Western blotting were performed as described
previously (Brown et al., 1999; Brown et al., 2000; Patil et al., 2000; Caserta et al.,
2003). Briefly, 100 μg of whole cell lysate was separated by SDS-PAGE and transferred
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to Immobilon-P polyvinylidene difluoride membrane. Protein transfer was empirically
determined by staining with 1.0% Ponceau S. following transfer (Brown et al., 1999;
Brown et al., 2000; Caserta et al., 2003). The membrane was incubated in blocking
buffer (60 mM Tris, 200 mM NaCl with 0.05% Tween 20 containing 5% nonfat dry milk,
pH 7.4) and incubated with a 1:1,000 dilution of primary antibody for 2 h at room
temperature. The blot was washed and then incubated with a 1:50,000 dilution of goat
anti-rabbit horseradish peroxidase secondary antibody for 1 h at room temperature and
processed using the Supersignal chemiluminescence reagent according to manufacturer’s
instructions.

Cell Proliferation and Viability Assay
Jurkat human T cells (1 × 105 cells/ml) were treated for 72 hrs with vehicle (V),
cell death inducer 1 μg/ml actinomycin D, 100 μM Q-VD-OPh or 100 μM Q-VE-OPh.
Cell viability was determined by cell count and trypan blue staining at 24 hr intervals.

Tissue Collection and Sectioning
All animal studies were in accordance with policies and procedures of the
laboratory animal care and use committee. Mice were sacrificed by decapitation after
CO2 incapacitation and brain tissue was collected for histology. Whole brains were quick
frozen in isopentane for 20 seconds and then stored at -80°C until sectioning. Brain
tissue was mounted, covered with OCT Embedding Compound, and coronally sliced on a
cryotome (at approx. -24°C) at 10μm thickness. Sections were collected on Superfrost
Plus Microscope slides, dried overnight at room temperature, rehydrated in ethanol series
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(100%, 95%, and 70%) for 5 minutes each respectively, fixed in 4% paraformaldehyde
for 10 minutes, and either stored or stained. Slides were stored at -80°C after fixation
until needed for staining.

Hematoxylin and Eosin Staining
Slides were sequentially dipped in the following solutions: hematoxylin for 2
minutes, running tap water for 2 minutes, 50% ethanol for 2 minutes, 70% ethanol for 2
minutes, eosin for 15 secs, 95% ethanol for 1 min, 100% ethanol twice for 2 minutes, and
xylene twice for 2 minutes. Slides were coverslipped and mounted in permount.

Diaminobenzidine (DAB) Stain
Sections were blocked in a 6% hydrogen peroxide solution in methanol for 10
minutes. In some cases, an additional avidin-biotin block was used after 6% hydrogen
peroxide block, where avidin solution was first used for 15 minutes, followed by a biotin
solution for 15 minutes. Slides were then washed 4 times in 1 x phosphate buffer saline
(1x PBS) for 2 minutes each after each solution was applied to sections. Avidin-Biotin
Conjugate (ABC) solution was applied to slides that contained the additional avidin and
biotin block for 1.5 hours. All slides were then immersed in DAB solution for 4 minutes
followed by 4 washes in double distilled water for 2 minutes each. Slides were immersed
in a blue counterstain for 2 minutes and then dipped 10 times into 70% ethanol, 95%
ethanol, 100% ethanol, and xylene respectively (2 changes each). Sections were
coverslipped and mounted using clearmount medium.
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Terminal deoxynucleotidyl transferase-mediated biotinylated UTP Nick End Labeling
(TUNEL)
TUNEL staining was performed on brain sections using the NeuroTACS II In Situ
Apoptosis Detection Kit. The following modifications were made to the assay protocol
to improve the contrast of stains and to decrease background. The quenching solution
was increased from 3% hydrogen peroxide to 6% hydrogen peroxide for 10 minutes to
better block endogenous peroxidase in the brain. Slides were immersed in DAB solution
for 4 minutes. Washes after the quenching solution step were increased to 4 washes for 3
minutes. Two washes of 1% bovine albumin serum (BSA) and 0.05% tween in 1x PBS
for 2 minutes were added after the Strepavidin-HRP step followed by 2 additional 1x
PBS washes for 2 minutes. Washes after the DAB stain were followed by the protocol.
Sections were mounted using clearmount medium.

NeuN Immunohistochemsitry
Slides were fixed in 4% paraformaldehyde in 1x PBS and 0.1% trition solution
(1x PBS/T) for 10 minutes. An antigen retrieval step was performed using 1x citrate
buffer and boiled for 10 minutes. Sections were then washed 3 times for 5 minutes in (1x
PBS/T) and blocked in 10% normal goat serum for 30 minutes. An addition, sections
were blocked using 6% hydrogen peroxide in methanol followed by an avidin-biotin
block for 15 minutes. Slides were washed 4 times in 1x PBS for 3 minutes after each
blocking step. Sections were labeled with 1:100 anti-NeuN in 1x PBS overnight at 4°C
and then washed as previously described. Secondary antibody was applied at 1:1000
anti-mouse biotinylated made in goat in 1x PBS/T for 1.5 hours at 4°C and then washed.
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Avidin-Biotin Conjugate was applied to sections for 1 hour and washed in 1% BSA and
0.05% tween in 1x PBS twice for 3 minutes followed by 2 additional washes in 1x PBS
for 3 minutes. Sections were then labeled with DAB and washed 4 times for 2 minutes in
double distilled water. Slides were immersed in a blue counterstain for 2 minutes and
then dipped 10 times into 70% ethanol, 95% ethanol, 100% ethanol, and xylene
respectively (2 changes each). Sections were mounted using clearmount medium.
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III. RESULTS

Q-VE-OPh, a negative control
In order to validate Q-VD-OPh effectiveness in preventing neuronal death in
sarin-exposed mice, we needed to develop an appropriate negative control. Knowing that
the aspartic acid residue on Q-VD-OPh is crucial for inhibition, the caspase inhibitor
analog Q-VE-OPh was synthesized as an equivalent dipeptide amino acid analog similar
to the broad-spectrum caspase inhibitor, Q-VD-OPh. The aspartic acid (D) in Q-VD-OPh
was replaced with glutamic acid (E) to generate a nearly identical compund, Q-VE-OPh
(Figure 9).
To determine the ability of Q-VE-OPh to inhibit apoptosis, Jurkat T leukemia
cells were first treated with Q-VE-OPh followed by actinomycin D for 4 hours and
analyzed by DNA ladder assay (Figure 10). Actinomycin D alone induced substantial
apoptosis after 4 hours, as determined by the presence of a classic DNA ladder.
Incubation with vehicle, Q-VD-OPh, or Q-VE-OPh alone did not induce apoptosis. Preincubation with Q-VD-OPh for 30 minutes followed by 4 hours of actinomycin D
treatment prevented DNA laddering as low as 5μM of Q-VD-OPh. In contrast, Q-VEOPh co-incubation with actinomycin D did not prevent DNA laddering in the effective 520μM range for Q-VD-OPh. Partial DNA ladder inhibition was observed at 100 μM of
Q-VE-OPh. This indicates that Q-VE-OPh is at least 20 times less effective at inhibiting
apoptosis than the caspase inhibitor Q-VD-OPh. Apoptosis is dependent upon caspase
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Figure 9: Chemical structure of Q-VE-OPh and Q-VD-OPh.
The aspartic acid (D) in Q-VD-OPh was replaced to glutamic acid (E) to generate
the negative control, Q-VE-OPh.
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Figure 9
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Figure 10: Q-VD-OPh and Q-VE-OPh effects on apoptotic DNA laddering in Jurkat
Cells.
Jurkat cells (1 x 106 cells/ml) were treated for 4 hrs with vehicle (V), 1μg/ml
actinomycin D (AD), drug alone 100μM (D), or various concentrations (1, 5, 10, 20, 50,
or 100μM) of Q-VE-OPh (A) or Q-VD-OPh (B); preincubated 30 mins, prior to
actinomycin D addition. DNA was analyzed by isolation and evaluation of cytosolic
DNA on a 1.2% agarose gel. (M) indicates a Hi Lo DNA molecular weight marker.
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Figure 10
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activation which is dependent on the cleavage of specific caspase enzymes. To further
confirm the inability of Q-VE-OPh to inhibit caspase activation at relevant
concentrations, human initiator caspases 8 and 9 activation were analyzed by Western
blot analysis (Figure 11). Pro-caspase 8 and pro-caspase 9 were present in vehicle or QVD-OPh or Q-VE-OPh alone. Actinomycin D cleaved caspase 8 and 9 and therefore
activated the apoptosis pathway. Co-treated cells with Q-VD-OPh and actinomycin D
prevented cleaved-caspase 8 and cleaved-caspase 9. However, co-treated cells with QVE-OPh and actinomycin D did not prevent cleaved-caspase 8 and cleaved-caspase 9.
Therefore, Q-VD-OPh inhibited cleavage and activation of caspase 8 and 9, whereas QVE-OPh did not. The Western blot results confirm our DNA ladder findings that Q-VEOPh is a superior cognate negative control for Q-VD-OPh and O-Phenoxy caspase
inhibitor studies; when used within the correct and recommended concentration ranges.
Q-VD-OPh has previously been shown to be nontoxic (Caserta et al., 2003). To
determine if Q-VE-OPh was also nontoxic, cells were treated with Q-VE-OPh for 72
hours and cell viability was assessed (Figure 12). As anticipated, Q-VE-OPh
demonstrated no signs of toxicity and allowed undisrupted cell proliferation to occur over
the entire time course evaluated.

Immunohistochemistry optimizations
In order to analyze brains by immunohistochemistry, we first optimized brain
processing techniques of untreated mice using a hematoxylin and eosin (H&E) stain.
Drying the brain tissue overnight at room temperature after sectioning but before
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Figure 11: Western blot analysis on cleaved and activated caspase 8 and 9.
Q-VE-OPh does not prevent initiator caspase 8 or caspase 9 activation. Jurkat
human T cells (1 × 106 cells/ml) were treated for 4 hrs with vehicle (V), 1 μg/ml
actinomycin D (AD), 20 μM Q-VD-OPh (QVD), 20 μM Q-VD-OPh preincubated 1 hr
prior to addition of 1 μg/ml actinomycin D (QVD + AD), 20 μM Q-VE-OPh (QVE), 20
μM Q-VE-OPh, preincubated 1 hr prior to addition of 1 μg/ml actinomycin D (QVE +
AD). 100 μg of whole cell lysate was separated by SDS-PAGE and Western blotting was
performed using rabbit polyclonal antibody to caspase 8 (A) and caspase 9 (B), and
developed using Supersignal chemiluminesence. Arrows indicate the molecular weights
of the inactive proforms as well as the cleaved and activated forms of caspase 8 and 9.
Faint cleavage fragments seen in the vehicle and Q-VE-OPh lanes in (A) are due to a low
level of background apoptosis. Equal protein loading was present in all lanes (data not
shown).
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Figure 12: Percent viability on Jurkat T leukemia cells treated with vehicle, Q-VDOPh, Q-VE-OPh, or Actinomycin D.
Q-VE-OPh is not toxic. Jurkat human T cells (1 × 10 5 cells/ml) were treated for
72 hrs with vehicle (V), 1 μg/ml actinomycin D (AD), 100 μM Q-VD-OPh (QVD) or 100
μM Q-VE-OPh. Cell viability was determined by trypan blue staining of cells at 24 hr
intervals.
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Figure 12
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fixation and staining was critical in order to preserve the quality of the tissue (Figure 13).
The brain contains cerebrospinal fluid and therefore is critical to dry the tissue section out
thoroughly to prevent water from separating the tissue. Drying allows the tissue to
properly expand and has a better morphological appearance.
In vivo sarin experiments will be performed by MRI Global, Kansas City, MO.
Brains will be sectioned and placed on slides to be sent to us. Not all sarin slides will be
analyzed in one day and will need to be stored in the -80°C. Therefore we need to
determine the best way to handle slides when taking them out of the freezer. Mouse
brains will be sectioned, dried overnight, fixed, and then stored in the -80°C. To
determine if slides need to be redried and/or the amount of time slides should dry after
storage, we used a DAB stain to examine background and an H&E stain to look at tissue
quality. Storing slides did not create any background issues or freezer burn when either
redried overnight at room temperature, redried for 2 hours at room temperature, or not
drying at all (Figure 14). Slides should be stored in a slide holding box that is in a freezer
bag to prevent freezer burn (data not shown). An H&E stain showed that it is necessary
to redry slides overnight at room temperature to prevent holes in the tissue (Figure 15).
Holes in the tissue from not properly drying slides from the freezer could appear as
artifacts in sarin treated sections.
Next, we optimized Tunel assay and NeuN staining in untreated mice by
decreasing background and increasing contrast between the stain and the background.
Tunel assay works by detecting cell death in both apoptotic and necrotic cells. In order to
label cell death in untreated mice, a nuclease was used to fragment the DNA as a positive
control. The labeling procedure includes using a terminal deoxynucleotidyl
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Figure 13: Optimizing brain processing techniques by Hematoxylin and Eosin Stain
The order of sectioning, drying, fixing, and staining were varied. Brain tissue was
sectioned, fixed, and stained (A). Brain tissue was sectioned, fixed, dried overnight, and
stained (B). Brain tissue was sectioned, dried overnight, fixed, and stained (C).
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Figure 14: DAB stain on stored slides in -80°C freezer.
Slides were sectioned, dried overnight at room temperature, fixed, and stored in
the -80°C freezer for two weeks. Slides were taken out of the -80°C freezer and were
either redried overnight at room temperature, dried for 2 hours at room temperature, or
not dried. Sections were blocked in 6% H 2O2 for 10 mins and labeled with DAB.
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Figure 15: H&E stain on stored slides in -80°C freezer.
Slides were sectioned, dried overnight at room temperature, fixed, and stored in
the -80°C freezer for two weeks. Slides were taken out of the -80°C freezer and were
either redried overnight at room temperature, dried for 2 hours at room temperature, or
not dried. Sections were stained with hematoxylin and eosin
.
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Figure 15
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transferase (TdT) to transfer a deoxynucleotide triphosphate (dNTP) molecule connected
to biotin on to the ends of DNA breaks, then adding a strepavidin-horse radish peroxidase
(HRP) to biotin, and finally labeling the DNA breaks by immersing the slides into a
diaminobenzidine (DAB) solution. The HRP will oxidize DAB, thereby labeling DNA
breaks in the cell brown (Figure 16). Elimination of Tdt (-Tdt) in the Tunel assay serves
as a negative control for background staining. NeuN staining works by using a
monoclonal primary antibody that stains the nuclei and cytoplasm of most neuronal cell
types in all regions of the adult brain (Mullen et al., 1992). A biotinylated secondary is
used to recognize the primary antibody. Next, an avidin-biotin conjugate (ABC) is used
to bind to the biotin of the secondary. The biotin has HRP attached to it so that DAB can
label neurons brown (Figure 17).
To prevent false labeling in both Tunel assay and NeuN staining, we had to block
endogenous peroxidase (Yamaguchi and Eto, 1983). First we determined an optimal
concentration and timing for a peroxidase blocker using DAB solution on sections only.
3% hydrogen peroxide (H2O2) was used at 0, 3, 5, 10, 15, 30, and 45 minutes to quench
endogenous peroxidase in brain sections. The optimal time to prevent peroxidase using
3% H2O2 was 45 minutes (Figure 18). We also used 6% H2O2 at 0, 3, 5, 10, 15, 30, and
45 minutes and found 10 minutes of 6% H2O2 was optimal at this concentration (Figure
19). In comparing no block, 3% H2O2 for 45 minutes, and 6% H2O2 at 10 minutes, we
observed that 6% H2O2 for 10 minutes eliminated peroxidase activity the best and used it
in all future stainings (Figure 20).
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Figure 16: Tunel Assay
Tunel assay detects cell death in necrotic or apoptotic cells. A nuclease is used to
fragment the DNA to optimize labeling in untreated mice. The labeling procedure
includes using a terminal deoxynucleotidyl transferase (TdT) to transfer a
deoxynucleotide triphosphate (dNTP) molecule connected to biotin on to the ends of
DNA breaks (A), then adding a strepavidin-horse radish peroxidase (HRP) to biotin (B),
and finally labeling the DNA breaks by immersing the slides into a diaminobenzidine
(DAB) solution (C).

52

Figure 16

Modified from the protocol in NeuroTACS II In Situ Apoptosis Detection Kit.
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Figure 17: NeuN Staining
Neurons were labeled using anti-NeuN primary antibody (A). The biotinylated
secondary, anti-mouse, was used to bind the primary antibody (B). Next, an avidin-biotin
conjugate (ABC) attached to the biotin of the secondary (C). The biotin has HRP (D)
connected to it so that DAB (E) can label neurons brown.
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Figure 18: 3% H2O2 Block
Slides were blocked in 3% hydrogen peroxide (H 2O2) for 0, 3, 5, 10, 15, 30, and
45 mins to quench endogenous peroxidase in brain sections and labeled using DAB.
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Figure 18
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Figure 19: 6% H2O2 Block
Slides were blocked in 6% hydrogen peroxide (H 2O2) for 0, 3, 5, 10, 15, 30, and
45 mins to quench endogenous peroxidase in brain sections and labeled using DAB.
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Figure 19
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Figure 20: Optimal peroxidase block
Compares the optimal block between no block, 3% H 2O2 block for 45 mins, or
6% H2O2 block for 10mins. Sections labeled using DAB.
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Figure 20
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We also had to block endogenous biotin found in the brain (Zempleni et al., 2009)
for NeuN staining by using an avidin-biotin blocker. To determine optimal timing of
avidin-biotin blocking, we used an avidin-biotin blocker, ABC, and DAB solution.
Avidin-biotin blocker was used for 0, 5, 15, and 30 minutes. At 15 minutes, the avidinbiotin blocker eliminated labeling of endogenous biotin (Figure 21).
DAB timing was optimized to create maximum contrast between the staining of
the nuclei and the background. Tunel assay was performed and DAB times were varied
from 0-7 minutes. At 4 minutes there was enough contrast to distinguish the brown
staining of DNA fragments in the nuclei (Figure 22). DAB time of 4 minutes can also be
used for NeuN staining.
To further eliminate background in Tunel assay and NeuN staining, we rinsed off
labeling residue by using 1% bovine serum albumin (BSA) and 0.05% tween wash (BSAT) after the strep-avidin HRP or ABC labeling step. BSA stabilizes enzymes and tween
is a detergent. In both positive and negative controls, BSA-T rinsed off any additional
residue from the labeling steps on the brain section (Figure 23). In addition to a BSA-T
wash, the number of washes after each blocking step and labeling step is important.
Using a 3% H2O2 for 5 minutes and a DAB label, we found it was necessary to wash
slides 4 times in 1x PBS after the peroxidase blocking step to rinse off extra hydrogen
peroxide (Figure 24).
The CA1, CA2, CA3, and dentate gyrus of the hippocampus are the main regions
sarin could cause neuronal death in mouse brain, therefore our Tunel assay pictures will
be of the hippocampus (Paxinos and Franklin, 2001)(Figure 25). In order to decrease
background in Tunel assay of the mouse brain, we made several modifications to the
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Figure 21: Avidin-Biotin Block
Slides were blocked in 6% H2O2 for 10 mins, avidin-biotin block for 0, 5, 15, and
30mins to quench endogenous biotoin in brain sections and labeled using avidin-biotin
conjugate (ABC) and DAB.
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Figure 22: Optimization of DAB timing in Tunel assay
Sections were blocked using 6% H 2O2 for 10 mins, avidin-biotin block for 15
mins, and labeled with DAB for 0, 0.5, 1, 4, or 7 mins.
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Figure 22
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Figure 23: Bovine Serum Albumin and Tween (BSA-T) Wash
Sections were washed twice in 1% BSA and 0.05% tween for 3 mins after the
strepavidin-HRP step of the Tunel assay in both positive (+ nuclease) and negative (- Tdt)
controls. Sections were washed two additional times in 1x PBS.
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Figure 23

74

75

Figure 24: Washes in 1x PBS
Sections were blocked using 3% H 2O2 for 10 mins, washed 0, 1, 2, or 3 times with
1x PBS, and labeled with DAB for 4 mins.
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Figure 24
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Figure 25: Hippocampus of mouse brain
The outer box represents a section of the mouse brain that contains the
hippocampus. The inset outlines the hippocampus which is the main region of the brain
where neuronal death is found after sarin exposure. The hippocampus consists of the
CA1, CA2, CA3, and dentate gyrus (DG) regions.
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Figure 25

Paxinos G and Franklin K. The mouse brain in stereotaxic coordinates. 2 nd ed. San
Diego, Calif: Academic. 2001.
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NeuroTACS II In Situ Apoptosis Detection Kit’s Tunel assay protocol: 1. Increased
hydrogen peroxide block from 3% for 5 minutes to 6% for 10 minutes. 2. Increased
washes from 1 wash of 1x PBS for 2 minutes to 4 washes of 1x PBS for 3 minutes after
each blocking and labeling step. 3. Added two 1% BSA and 0.05% tween wash steps
after the strepavidin-HRP labeling step for 3 minutes followed by two additional washes
in 1x PBS. 4. Determined that sections needed to be stained with DAB for 4 minutes to
created optimal contrast between brown stain of nuclei to the background. Background
on Tunel assay on mouse brain dramatically decreased after these modifications (Figure
26). A close up of the Tunel assay of the CA1 region of the hippocampus shows good
contrast between the brown labeling of fragmented DNA and the other cells (Figure 27).
In our sarin experiments, we will show that neurons of the hippocampus die in
sarin treated mice. We developed a protocol for NeuN staining in mouse brain by
making modifications to the suggested protocol that included the same modifications as
the Tunel assay and an additional 15 minutes avidin-biotin block. Neurons were detected
in mouse brains not treated with sarin (Figure 28).
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Figure 26: Tunel assay before and after modifications
Background decreases in Tunel assay after modifications are made to the
NeuroTACS II In Situ Apoptosis Detection Kit’s protocol. Pictures are shown of both
positive and negative controls before modifications (A) and after modifications (B).
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Figure 26
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Figure 27: Tunel assay of the CA1 region
Both positive and negative control pictures of Tunel assay of the CA1 region of
the hippocampus in mouse brain at 40X.
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Figure 27
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Figure 28: NeuN Staining
Neurons were labeled brown by DAB in untreated mouse brains.
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Figure 28
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IV. DISCUSSION

Q-VE-OPh was designed to identify and characterize an analog of the widely used
in vivo, broad-spectrum caspase inhibitor, Q-VD-OPh. In order to create this analog, the
aspartic acid residue on Q-VD-OPh was replaced with a glutamic acid residue. The only
difference between the two molecules is that Q-VE-OPh has the addition of a single
carbon ion on the aspartic acid residue of Q-VD-OPh. Therefore Q-VE-OPh is nearly
identical due to the same charge and similar mass (data not shown). It was anticipated
that this small addition would change Q-VE-OPh’s effectiveness as a caspase inhibitor in
cell culture. Q-VE-OPh was unable to inhibit DNA fragmentation or caspase activation
at relevant concentrations. This implies that the specificity of Q-VD-OPh binding pocket
to caspases is high and that a single addition of a carbon is enough to alter its binding
capabilities. Based on the concentrations, Q-VE-OPh was 20 times less effective than QVD-OPh, which provides it as an optimal negative control at effective concentrations.
Furthermore, Q-VE-OPh is not toxic over time. Q-VD-OPh has been widely used in vivo
for extended periods of time and is recommended for use due to its lack of toxicity. It is
likely that the –OPh moiety eliminates in vivo toxicity and that the use of Q-VE-OPh as a
negative control for caspase inhibitors in vivo will also have no associated toxicity.
The current negative control for caspase inhibitors is Z-FA-fmk (ZPhenylalanine-Alanine-fluro methyl ketone). Surprisingly, this does not represent a true
negative control for caspase inhibitors because it inhibits effector caspases which will
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lead to preventing apoptosis (Lopez-Hernandez et al., 2003; Gezginci-Oktayoglu et al.,
2008). It is also not specific towards caspases in cell death since it also inhibits cathepsin
B, which is a lysosomal cysteine protease (Lawerence et al., 2006). In addition to it
being a poor negative control, its use in vivo is not reasonable because of its toxicity due
to the accumulation of fluoroacetate (Eichhold et al., 1997; Van Noorden 2001; Caserta
et al., 2003).
In conclusion, we have produced and determined the effectiveness of a novel and
appropriate negative control, Q-VE-OPh, for the broad-spectrum caspase inhibitor QVD-OPh (Southerland et al., 2010). It provides a new and useful tool to confirm the
specificity of O-phenoxy caspase inihibitors when studying mammalian apoptosis both in
vitro and in vivo.
Q-VE-OPh will serve as a negative control in experiments where mice are
exposed to sarin. Mice will be injected with sarin and treated with Q-VD-OPh or Q-VEOPh 30 minutes post sarin and their brain tissue will be collected 2 and 14 days later for
immunohistochemistry analysis. Neuronal death is expected to be found at day 2,
whereas inflammation is expected to be highest at day 14. We will analyze these days to
see if Q-VD-OPh decreases neuronal death and inflammation.
Our studies showed that Q-VD-OPh can prevent apoptosis when given 30 minutes
prior to being induced to die apoptotically with actinomycin D. However, in a situation
when a person is exposed to sarin, Q-VD-OPh would be injected after sarin exposure. In
cells, Q-VD-OPh can be given 30 minutes after treatment with actinomycin D to prevent
apoptosis (data not shown). After that time period, Q-VD-OPh will not be able to
prevent apoptosis because certain events would have taken place late in the apoptotic
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pathway. Therefore, in a real situation of being exposed to sarin, one would need to take
Q-VD-OPh shortly after being exposed in order to prevent neuronal damage in the brain.
Since sarin’s use in experimental applications is highly restricted and regulated by
the US Department of Defense, it can only be used in two places in the United States.
Therefore, it is first critical to optimize each assay in untreated mice or mice not exposed
to sarin before proceeding with experimental slides.
We optimized mouse brain processing techniques, storage conditions, and the
immunohistochemistry assays in untreated mouse brain. The quality of the stains is
affected if the brain tissue has not been properly dried out. Since the brain has a high
fluid content from the cerebrospinal fluid, we found it critical to let the brain sections sit
out overnight at room temperature to thoroughly dry the tissue. Drying the tissue will
enhance morphological appearance of stains. We also found that it is best to redry the
brain sections overnight at room temperature after storing in the -80°C freezer. The
sections have water on them from being out in the open and when stored in the freezer,
the water will form ice crystals. When slides are removed from the -80°C freezer, they
need to be returned to room temperature and redried in order to prevent holes in the
tissue. Sarin causes lesions in the brain, thus these holes may be artifacts in sarin treated
mice brains if sections are not thoroughly dried.
In our immunohistochemistry analysis, we will detect neuronal death in the brains
of sarin-exposed mice treated with Q-VD-OPh or Q-VE-OPh by doing a Tunel assay.
Tunel assay labels DNA double stranded breaks in the cells brown due to the
diaminobenzidine (DAB) label. DAB will be turned brown after being oxidized by
strepavidin-HRP from the Tunel assay labeling procedure as well as from endogenous
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peroxidase in the brain (Yamaguchi and Eto, 1983). Therefore, a peroxidase blocker is
needed to prevent false labeling of neuronal death. Hydrogen peroxide treatment on
brain sections will quench any peroxidase activity. The generic protocol from the
NeuroTACS II In Situ Apoptosis Detection Kit suggested a 3% H 2O2 in methanol for a 5
minute treatment to block peroxidase activity in tissues. We determined that an increase
from 3% H2O2 to 6% H2O2 solution in methanol for 10 minutes is necessary to block
peroxidase activity in brain tissue. Too much hydrogen peroxide could cause DNA
damage in cells and create false Tunel positive cells (Stadelmann and Lassmann, 2000).
There were no additional Tunel positive cells in our sections that showed untreated cell
death in the brain between 3% H 2O2 and 6% H2O2 blocks (data not shown). This implies
that increasing the hydrogen peroxide concentration to 6% for 10 minutes did not
produce any false Tunel positive cells. Furthermore, washing off additional blocking or
labeling residue from the sections is important to eliminate background in stains.
NeuroTACS II In Situ Apoptosis Detection Kit protocol suggest one wash after the
hydrogen peroxide blocking step. We determined that 4 washes of 1x PBS are necessary
to rinse off all extra blocking or labeling residue. In addition, two washes of 1% bovine
serum albumin (BSA) and 0.05% tween (BSA-T) for 3 minutes each after the strepavidin HRP labeling step will aide in further rinsing off any extra labeling residue. This
decreases the background staining to have a cleaner Tunel assay. One other Tunel assay
optimization was to determine the amount of time DAB should be on sections to label
DNA breaks in cells. Four minutes of immersing slides into a DAB solution was optimal
to clearly observe cell death in brain tissue.

92

Tunel assay detects in situ DNA fragmentation of both apoptotic and necrotic cell
death (Gavrieli et al., 1992; Stadelmann and Lassmann, 2000). Sarin-induced seizures
can cause both apoptosis and necrosis. DNA fragmentation during apoptosis is induced
by caspase-mediated cleavage of caspase-activated DNase which produces the
characteristic internucleosomal DNA double strand breaks of 180-200 base pairs and can
be detected by dark brown staining of the nuclei in Tunel assay. However, other
fragments of 50-150 base pairs are also generated that lack the prototypical
internucleosomal pattern of DNA fragmentation, such as in necrotic cell death. It is
worth noting that Tunel positive cells that are necrotic may appear to have a lighter stain
because of the smaller fragments throughout the cell (Stadelmann and Lassmann, 2000).
Further immunohistochemistry analysis includes detecting damage neurons in
sarin-exposed mice by labeling neurons with NeuN. The same 6% H2O2 block used in
the Tunel assay will be used for the NeuN staining to prevent false labeling of neurons
since a DAB stain is used. In addition to a peroxidase block, a biotin blocker is needed
for the NeuN staining, whereas it is not needed for the Tunel assay. Biotin is a vitamin
essential for metabolism and is widely distributed in the body (Dakshinamurti and
Chauhan, 1989). The CA3 and CA4 regions of the hippocampus were specifically found
to be positive for endogenous biotin (Wang and Pevsner, 1999). The avidin-biotin
conjugate (ABC) will bind to biotinylated secondary antibody and also endogenous biotin
in the brain (Zempleni et al., 2009). We found it necessary to use an avidin-biotin
blocker for 15 minutes to block endogenous biotin in a DAB stain. The same washing
optimizations and DAB timing used in the Tunel assay will be used for NeuN staining.
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In future studies, mice will be injected with sarin and then treated with Q-VDOPh or Q-VE-OPh 30 minutes post sarin and brains will be collected 2 and 14 days for
immunohistochemistry analysis. In our immunohistochemistry analysis, we will
demonstrate by Tunel assay that cell death occurs in sarin-exposed mice and that cell
death is decreased or eliminated in Q-VD-OPh treated sarin-exposed mice by Tunel
assay. Second, we will illustrate that cell death is found in neurons by labeling the cells
with a neuronal neuron antibody (NeuN). Third we will confirm that neuronal death is
activated by caspases by the detection of caspase 3 antibody. We expect to see a
decrease in neuronal death and in caspase 3 activation in sarin-exposed mice treated with
Q-VD-OPh compared to sarin-exposed mice treated with Q-VE-OPh.
The type of mice chosen is very important. Factors to take into consideration are
the age and gender of the mice. The stage of maturity the brain is in can affect whether
death occurs by apoptosis or necrosis. The apoptotic pathway was shown to occur in an
immature region of the brain in neonatal mice (Lopez-Meraz et al., 2010b). Thus, Q-VDOPh may work better in neonatal mice. However, people who are likely to be exposed to
a nerve agent will be adults, it is necessary to use adult mice. Gender may be an issue
because one study showed a decrease in cell death in Q-VD-OPh treated postnatal-day 7
female rats but not male rats after neonatal stroke (Renolleau et al., 2007). Females were
found to have a significant neuroprotection using Q-VD-OPh because they have a
caspase-dependent cell death pathway whereas males appear to be independent
(Renolleau et al., 2008). However, this was in neonatal rats and not adult rats. The male
rat brains may have matured faster than the female rat brains; therefore our study should
be done using both genders. In addition, mice have enzymes, called carboxylesterases,
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which act as scavengers by acting irreversibly with organophosphorus compounds and
removing them before they react with actylcholinesterase (Fonnum, 1981; Maxwell et al.,
1987). This would affect sarin’s exposure on mice and interfere with results, therefore,
we will treat C57Bl/6 mice with cresylbenzodioxaphosphorin oxide to inhibit
carboxylesterase scavengers in a murine model optimized for sarin exposure (Garrett et
al., 2010).
Studies have demonstrated that CA1 neurons can die by a caspase-dependent,
active-form of necrosis after status-induced epilepticus with necrotic morphology and
caspase 3 activation (Lopez-Meraz et al., 2010a). In these studies, Q-VD-OPh prevented
neuronal degeneration by 44% (Lopez-Meraz et al., 2010a; Lopez-Meraz et al., 2010b).
Seizures that are triggered by sarin may induce apoptotic or necrotic neuronal death. We
expect Q-VD-OPh to block both cell death types due to the presence of caspase
activation.
To summarize, we designed and synthesized a negative control to analyze
neuronal death in sarin-exposed mice treated with Q-VD-OPh. We also optimized the
Tunel assay and NeuN staining in untreated mice. These labeling procedures will be
used to detect neuronal death in the hippocampus of sarin-exposed mice treated with QVD-OPh or Q-VE-OPh.
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V. APPENDIX
Appendix A: List of Abbreviations
ABC

avidin-biotin conjugate

Apaf-1

apoptotic protease activating factor-1

BH3

Bcl-2-homology 3

BSA

bovine serum albumin

DAB

diaminobenzidine

DG

dentate gyrus

Diablo

direct IAP-binding protein with low pI

DISC

death-inducing signaling complex

EEG

electroencephalogram

FADD

Fas-associated death domain

fmk

fluoromethylketone

H&E

hematoxylin and eosin

HRP

horse radish peroxidase

H2O2

hydrogen peroxide

NeuN

neuronal neuron

PBS

phosphate buffer saline

PBS/T

phosphate buffer saline / triton

Q-VD-OPh

quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxyl]-methyl
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ketone
Q-VE-OPh

quinolyl-valyl-O-methylglutaryl-[2,6-difluorophenoxyl]-methyl
ketone

Smac

second mitochondrial-derived activator of caspases

Tunel

terminal deoxynucleotidyl transferase-mediated biotinylated UTP
nick end labeling
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